Laurence T Rimsky
Overview
Explore the profile of Laurence T Rimsky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
535
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Van Eygen V, Thys K, Van Hove C, Rimsky L, De Meyer S, Aerssens J, et al.
J Med Virol
. 2015 Sep;
88(5):798-806.
PMID: 26412111
Minority variants (1.0-25.0%) were evaluated by deep sequencing (DS) at baseline and virological failure (VF) in a selection of antiretroviral treatment-naïve, HIV-1-infected patients from the rilpivirine ECHO/THRIVE phase III studies....
2.
Picchio G, Rimsky L, Van Eygen V, Haddad M, Napolitano L, Vingerhoets J
Antivir Ther
. 2014 Apr;
19(8):819-23.
PMID: 24704709
Background: The prevalence of rilpivirine resistance-associated mutations (RAMs) in the USA, and their effect on phenotypic susceptibility to rilpivirine and etravirine, was evaluated in clinical samples from HIV-1-infected patients. Methods:...
3.
Cohen C, Molina J, Cahn P, Clotet B, Fourie J, Grinsztejn B, et al.
J Acquir Immune Defic Syndr
. 2012 Feb;
60(1):33-42.
PMID: 22343174
Background: Pooled analysis of phase 3, double-blind, double-dummy ECHO and THRIVE trials comparing rilpivirine (TMC278) and efavirenz. Methods: Treatment-naive HIV-1-infected adults were randomized 1:1 to rilpivirine 25 mg once daily...
4.
Wilkin A, Pozniak A, Morales-Ramirez J, Lupo S, Santoscoy M, Grinsztejn B, et al.
AIDS Res Hum Retroviruses
. 2011 Sep;
28(5):437-46.
PMID: 21902621
TMC278-C204 (NCT00110305), a 96-week trial of the nonnucleoside reverse transcription inhibitor (NNRTI) rilpivirine (RPV, TMC278) in 368 HIV-1-infected, treatment-naive patients, was extended to investigate long-term safety and efficacy. Week 192...
5.
Molina J, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, et al.
Lancet
. 2011 Jul;
378(9787):238-46.
PMID: 21763936
Background: Efavirenz with tenofovir-disoproxil-fumarate and emtricitabine is a preferred antiretroviral regimen for treatment-naive patients infected with HIV-1. Rilpivirine, a new non-nucleoside reverse transcriptase inhibitor, has shown similar antiviral efficacy to...
6.
Cohen C, Andrade-Villanueva J, Clotet B, Fourie J, Johnson M, Ruxrungtham K, et al.
Lancet
. 2011 Jul;
378(9787):229-37.
PMID: 21763935
Background: The non-nucleoside reverse transcriptase inhibitor (NNRTI), rilpivirine (TMC278; Tibotec Pharmaceuticals, County Cork, Ireland), had equivalent sustained efficacy to efavirenz in a phase 2b trial in treatment-naive patients infected with...
7.
Azijn H, Tirry I, Vingerhoets J, de Bethune M, Kraus G, Boven K, et al.
Antimicrob Agents Chemother
. 2009 Nov;
54(2):718-27.
PMID: 19933797
Nonnucleoside reverse transcriptase inhibitors (NNRTIs) have proven efficacy against human immunodeficiency virus type 1 (HIV-1). However, in the setting of incomplete viral suppression, efavirenz and nevirapine select for resistant viruses....
8.
Pozniak A, Morales-Ramirez J, Katabira E, Steyn D, Lupo S, Santoscoy M, et al.
AIDS
. 2009 Nov;
24(1):55-65.
PMID: 19926964
Objective: TMC278 is a next-generation nonnucleoside reverse transcriptase inhibitor highly active against wild-type and nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 in vitro. The week 96 analysis of TMC278-C204, a large dose-ranging...
9.
Tambuyzer L, Azijn H, Rimsky L, Vingerhoets J, Lecocq P, Kraus G, et al.
Antivir Ther
. 2009 Mar;
14(1):103-9.
PMID: 19320243
Background: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are an important component of antiretroviral therapy for HIV type-1 (HIV-1)-infected patients. Development of NNRTI resistance can lead to treatment failure and is conferred...